Stock VSC 4SC AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials 4SC AG Xetra

Equities

VSC

DE000A14KL72

Biotechnology & Medical Research

End-of-day quote Xetra
Other stock markets
 06:00:00 2023-02-07 pm EST 		5-day change 1st Jan Change
2.98 EUR -.--% Intraday chart for 4SC AG +14.62% -.--%
Mar. 22 4SC AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 83.06 98.84 79.39 35.5 12.95 89.51
Enterprise Value (EV) 1 58.02 54.89 44.75 7.878 -1.879 84.29
P/E ratio -4.7 x -5.27 x -3.83 x -3.49 x -0.9 x -10.9 x
Yield - - - - - -
Capitalization / Revenue 19.9 x 45 x 35.3 x 2.53 x 29.7 x 294 x
EV / Revenue 13.9 x 25 x 19.9 x 0.56 x -4.31 x 277 x
EV / EBITDA -3.33 x -3.72 x -2.3 x -0.92 x 0.14 x -10.7 x
EV / FCF -5.97 x -7.87 x -4.5 x -3.27 x 0.19 x -12.2 x
FCF Yield -16.7% -12.7% -22.2% -30.6% 522% -8.17%
Price to Book 2.92 x 2.05 x 2.12 x 1.28 x 0.97 x 17.7 x
Nbr of stocks (in thousands) 6,130 9,195 10,114 10,114 10,114 10,114
Reference price 2 13.55 10.75 7.850 3.510 1.280 8.850
Announcement Date 3/18/19 3/25/20 3/23/21 3/22/22 3/16/23 3/22/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 4.173 2.196 2.252 14.01 0.436 0.304
EBITDA 1 -17.45 -14.75 -19.42 -8.528 -13.06 -7.895
EBIT 1 -17.56 -14.87 -19.56 -8.65 -13.68 -8.426
Operating Margin -420.7% -677.19% -868.61% -61.74% -3,137.39% -2,771.71%
Earnings before Tax (EBT) 1 -17.56 -13.86 -18.99 -10.17 -14.36 -8.222
Net income 1 -17.66 -13.96 -18.99 -10.17 -14.36 -8.237
Net margin -423.17% -635.79% -843.16% -72.56% -3,293.81% -2,709.54%
EPS 2 -2.881 -2.038 -2.048 -1.005 -1.420 -0.8144
Free Cash Flow 1 -9.712 -6.972 -9.952 -2.411 -9.804 -6.888
FCF margin -232.74% -317.5% -441.9% -17.21% -2,248.71% -2,265.67%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/18/19 3/25/20 3/23/21 3/22/22 3/16/23 3/22/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 25 44 34.6 27.6 14.8 5.22
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -9.71 -6.97 -9.95 -2.41 -9.8 -6.89
ROE (net income / shareholders' equity) -48.3% -36.4% -44.3% -31.2% -70.2% -89.8%
ROA (Net income/ Total Assets) -27.7% -22.1% -25.6% -14.1% -34.7% -40.8%
Assets 1 63.71 63.25 74.1 72.05 41.41 20.18
Book Value Per Share 2 4.640 5.240 3.700 2.740 1.310 0.5000
Cash Flow per Share 2 4.080 3.450 2.390 1.000 1.470 0.8200
Capex 1 0.12 0.13 0.04 0.03 0 0
Capex / Sales 2.88% 6.06% 1.87% 0.24% 0.69% 0.66%
Announcement Date 3/18/19 3/25/20 3/23/21 3/22/22 3/16/23 3/22/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VSC Stock
  4. VSC Stock
  5. Financials 4SC AG